Skip to content
Review

Skeletal effects of GLP-1 receptor agonist therapy in adults with overweight or obesity: a systematic review

Oct 2026 · Archives of Osteoporosis · Vol 21 · 0 citations · 39 references
Medicine

TL;DR

This systematic review of eight randomized controlled trials evaluating dual-energy X-ray absorptiometry (DXA)-derived bone mineral density reports findings separately for each agent, without pooling, because the trials evaluated four pharmacologically distinct agents differing markedly in weight-lowering potency.

View source

Similar papers

Review Nov 2026

The effect of glucagon-like peptide-1 receptor agonists on bone metabolism: A systematic review and meta-analysis of randomized placebo-controlled trials of predominantly first-generation agents.

BACKGROUND Glucagon-like peptide-1 receptor agonists (GLP-1RAs) improve cardiometabolic outcomes, but their isolated effects on human bone remodeling remain uncertain because prior syntheses pooled heterogeneous study designs and active antidiabetic comparators. This systematic review and meta-analysis quantified the e...

M. Safargar, Navid Ahmadi, K. Prabahar et al. · 0 citations
Review Oct 2026

Effects of GLP-1–Related Therapies on Lean Mass and Body Composition: A Narrative Review

Glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) (GLP-1RAs) and incretin-based multiagonist therapies have become among the most widely prescribed medications for obesity and type 2 diabetes mellitus (T2DM) management, producing clinically meaningful reductions in body weight and fat mass (FM). Concerns have e...

Amanda Palmieri Ataei, Nima Ataei · 0 citations
Review Open access Oct 2026

Weight loss and blood pressure lowering with GLP-1 receptor agonists and multi-hormone receptor modulators in overweight and obesity: a systematic review and meta-regression of phase 3 clinical trials

Summary Background Obesity and hypertension frequently coexist, and weight-reduction is recommended as a core strategy for blood pressure (BP) management in adults with overweight or obesity. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and emerging multi-hormone receptor modulators (MHRMs) induce substantial w...

Massimo Nardone, L. Kugathasan, L. Daunt et al. · 0 citations
Review Open access Sep 2026

Skeletal Muscle Effects of GLP 1 Receptor Agonists: Molecular Mechanisms and Comparative Insights on Semaglutide and Tirzepatide, a Narrative Review

GLP-1 receptor agonists (GLP-1RAs), dual GLP-1/GIP agonists, and the more recent triple GLP-1/GIP/glucagon agonists have transformed the treatment of type 2 diabetes mellitus (T2DM) and obesity, resulting in significant weight reduction. However, a substantial proportion (20–40%) of this weight loss is attributable to...

D. Cautela, Valeria Incarbona, A. Lombardi et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.